Chimeric receptors with 4-1BB signaling capacity provoke potent cytotoxicity against acute lymphoblastic leukemia

By C. Imai, K. Mihara, M. Andreánsky, I. Nicholson, Pui Ch, T. Geiger, Dario Campana. Leukemia, 2004

815 citations recorded by the source corpus.

View Paper: https://www.semanticscholar.org/paper/5ba5eebe97853d2b48b8ca7ff0d0a69ef5073221

How researchers see this paper

The researchers whose trusted networks rank it highest, strongest advocate first. Every researcher gets a different order.

In Immunology

In Oncology

Citations in the corpus

CD19-targeted T cells rapidly induce molecular remissions in adults with chemotherapy-refractory acute lymphoblastic leukemia (2013, background): “Recently published reports from the UPenn demonstrate promising clinical outcomes in CLL patients treated with a second-generation CAR derived from initial studies published elsewhere (17) containing the 4-1BB costimulatory signaling domain.”
Chimeric Receptor mRNA Transfection as a Tool to Generate Antineoplastic Lymphocytes (2008, neutral): “This contains a leader sequence, an anti-CD19 single-chain variable region (scFv) antibody domain, a transmembrane domain, and two intracellular signal transduction domains derived from 4-1BB (CD137) and CD3-z ( z ) chains (Imai et al. , 2004).”
Structural design of engineered costimulation determines tumor rejection kinetics and persistence of CAR T cells (2015, positive): “Two types of second-generation CARs, using either CD28 (Maher et al., 2002) or 4-1BB (Imai et al., 2004) as signaling components have been used in patients and both have yielded dramatic outcomes.”
CD28 costimulation improves expansion and persistence of chimeric antigen receptor-modified T cells in lymphoma patients. (2011, background): “To provide the costimulation lacking in tumor cell targets and thereby overcome the above limitations, several groups have incorporated costimulatory endodomains, including CD28 (12), 4-1BB (13, 14), or OX40 (15), into CAR molecules (so-called secondgeneration CARs).”
Genetic modification of primary natural killer cells overcomes inhibitory signals and induces specific killing of leukemic cells. (2005, methodology): “The anti-CD19-ζ, anti-CD19-BB-ζ and anti-CD19-truncated (control) plasmids are described elsewhere.(21) The pMSCV-IRES-GFP, pEQPAM3(-E), and pRDF constructs were obtained from the St.”